Month: April 2024

Harvia Plc press release 25 April 2024 at 3:00 p.m. EESTHarvia invites investors, analysts and media representatives to its Capital Markets Day on Wednesday, 29 May 2024 at 10:30 a.m. EEST. The Capital Markets Day will be held as a hybrid event. Institutional investors, analysts and media representatives are welcome to attend the event in Muurame, Teollisuustie 1–7, Finland. The Capital Markets Day can also be followed as a live webcast at https://harvia.videosync.fi/2024-05-29-cmd. A recording of the webcast and materials will be available after the event at www.harviagroup.com. CEO Matias Järnefelt and other members of Harvia’s Management Team will host the event. During the CMD, the Management Team will present Harvia’s strategy update and targets as well as other topical themes. Those participating in the event on site are requested...

LUBLIN, Poland, April 25, 2024 (GLOBE NEWSWIRE) — An inherent feature of oncology is personalization, i.e., conversion from the fit-to-all strategy based on applying the same chemotherapy regimens to all patients with a specific type of cancer to therapy individually tailored to the patient. Traditional methods such as immunohistochemistry and fluorescence in situ hybridization depend on subjective assessment of tissue samples, sometimes leading to imprecise results. This can result in either under-treatment or over-treatment, highlighting the need for better diagnostics. Recently, the concept of HER2-low expression has been proposed, indicating low expression of the HER2, undetectable by standard methods, but still being a positive predictive factor, and therefore justifying the use of targeted therapy.Fig. 1 Current paradigm...

STOUGHTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET. Conference Call Information To access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q1 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website: www.collegiumpharma.com. The webcast will be available for replay on the Company’s...

SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline development program on Thursday, May 9, 2024, at 4:30 PM EDT. To access the webcast, please use the following link: 1Q24 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 13744142. A webcast replay will be available approximately three hours after the call and will be archived on the website for 90 days. About Achieve...

LEXINGTON, Mass., April 25, 2024 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the first quarter of 2024 ended March 31, 2024 before the market opens on Tuesday, May 7, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO.Event:   iSpecimen First Quarter 2024 Results Conference CallDate:   Tuesday, May 7, 2024Time:   8:30 a.m. Eastern TimeDial in:   1-800-717-1738 (U.S. Toll Free) or 1-646-307-1865 (International)Webcast:   https://viavid.webcasts.com/starthere.jsp?ei=1666705&tp_key=0ac1c8e17f     For...

TORONTO, April 25, 2024 (GLOBE NEWSWIRE) — Element Fleet Management Corp. (TSX:EFN) (“Element” or the “Company”), the largest publicly traded, pure-play automotive fleet manager in the world, today announced it has commenced operations in its newest global location in Singapore. This expansion marks a significant milestone in Element’s ongoing strategic initiative to enhance its global procurement capabilities and strategic sourcing relationships in Asia. In line with this expansion, Element is also pleased to announce it has entered into a collaboration agreement with BYD, the world’s leading new energy vehicle (NEV) manufacturer and power battery supplier. Element’s newly formed relationship with BYD reinforces a shared commitment to advancing sustainable, zero-emission solutions in the fleet management industry. It also complements...

~ Strong start to the year with 1Q24 financial results ~~ Reiterate 2024 financial outlook ~ PLANO, Texas, April 25, 2024 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended March 29, 2024. First Quarter 2024 Highlights (compared to First Quarter 2023, except as noted)Sales increased 10% to $415 million, with organic growth of 6%. GAAP net income increased $7 million to $21 million, an increase of 57%. Non-GAAP adjusted net income increased $10 million to $39 million, an increase of 33%. GAAP operating income increased $5 million to $39 million, an increase of 15%. Non-GAAP adjusted operating income increased $13 million to $63 million, an increase of 26%. GAAP diluted EPS increased $0.20 per share to $0.59 per share. Non-GAAP adjusted EPS increased $0.27 per share to...

Oral presentations include additional comparative data between EscharEx® and SANTYL®, and new analyses show strong correlation between wound bed preparation and wound healing Analyses validate the planned design and endpoints of the upcoming Phase III study YAVNE, Israel, April 25, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, announced today that recent clinical data from EscharEx® Phase II studies will be presented throughout May 2024 at the largest, most prestigious annual meetings in the field of chronic wound care: the European Wound Management Association (EWMA), the Wound Healing Society (WHS), and the Symposium on Advanced Wound Care (SAWC). The oral presentations on EscharEx will include:Comparative data of EscharEx vs. SANTYL® that...

Zscaler Digital Experience (ZDX) Copilot effortlessly unlocks network, device, and application performance insights in real-time to help quickly resolve issues impacting end users SAN JOSE, Calif., April 25, 2024 (GLOBE NEWSWIRE) — Zscaler, Inc. (NASDAQ: ZS), the leader in cloud security, today announced groundbreaking innovations – ZDX Copilot, Hosted Monitoring, and Data Explorer – to its Zscaler Digital Experience™ (ZDX™) service. The new ZDX Copilot, an AI assistant, instantly analyzes and harnesses knowledge from over 500 trillion data points daily across users, devices, networks, and applications, to provide IT operations, service desk, and security teams insights they need related to digital experience and performance. Teams can ask sequences of questions to effectively converse with Copilot, which...

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in protective communications, today announced plans to release financial results for its fiscal second quarter, ended March 31, 2024, after the market close on Tuesday, May 14, 2024. A conference call to discuss the fiscal second quarter 2024 financial results will be held at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Conference call details: Date: May 14, 2024Time: 4:30 p.m. Eastern / 1:30 p.m. Pacific Toll-Free Dial-In Number: (888) 390-3967 (U.S. & Canada)International Dial-In Number: (862) 298-0702Webcast: https://www.webcaster4.com/Webcast/Page/1375/50525 Please dial in 10 minutes prior to the start time and tell the operator you are calling in for the Genasys Fiscal Second Quarter 2024 Financial Results Call. Questions to...